Know Cancer

forgot password

A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Docetaxel in Patients With Advanced Solid Tumors

Phase 1
18 Years
Open (Enrolling)
Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Docetaxel in Patients With Advanced Solid Tumors


I. To determine the dose-limiting toxicities and identify the recommended phase II dose of
the combination of docetaxel and BKM 120 (P13K inhibitor BKM120) in patients with advanced
solid tumors.

II. To determine the safety and tolerability of this combination. III. To determine any
pharmacokinetic (PK) interaction between BKM12O and docetaxel.


I. To assess any preliminary evidence of efficacy with this combination in patients with
advanced cancers.

II. To evaluate PIK3CA mutations as predictive biomarkers of efficacy for the combination.

III. To evaluate PIK3CA polymorphisms and polymorphisms in BKM120 transport and metabolism
as predictors of toxicity and/or efficacy.

OUTLINE: This is a dose-escalation study of PI3K inhibitor BKM120.

Patients receive PI3K inhibitor BKM120 orally (PO) once daily (QD) and docetaxel
intravenously (IV) over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses
in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days.

Inclusion Criteria:

- Written informed consent granted prior to initiation of any study-specific screening
procedures, given with the understanding that the patient has the right to withdraw
from the study at any time, without prejudice

- Histologically or cytologically confirmed diagnosis of solid malignancy; patient
should have locally advanced, inoperable or metastatic solid tumor with at least one
site of measurable disease [if applicable] (per Response Evaluation Criteria in Solid
Tumors [RECIST] for solid tumors or the appropriate disease classification/criteria
for the target population)

- Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

- Life expectancy of >= 12 weeks

- Platelet count >= 100 x 10^9/L

- Absolute neutrophil count (ANC) >= 1.5 x 10^9

- Hemoglobin (Hgb) >= 9 gm/dl

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within upper
limits of normal (ULN) range (or =< 3.0 x ULN if liver metastases are present)

- Serum bilirubin within ULN range (or =< 1.5 x ULN if liver metastases are present; or
total =< 3.0 x ULN with direct bilirubin within normal range in patients with well
documented Gilbert Syndrome)

- Serum creatinine =< 1.5 x ULN or 24-hour clearance >= 50 mL/min

- Serum amylase =< ULN

- Serum lipase =< ULN

- Fasting plasma glucose =< 120 mg/dl

- International normalized ratio (INR) =< 2

- Magnesium >= the lower limit of normal

- Potassium within normal limits

- Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use
for malignant hypercalcemia control is not allowed)

- Women of childbearing potential must have a negative pregnancy test performed within
48 hours prior to the start of study drug

- Male and female subjects of child-bearing potential must agree to use double-barrier
contraceptive measures, oral contraception, or avoidance of intercourse during the
study and for 90 days after last investigational drug dose received

Exclusion Criteria:

- Previous anti-cancer chemotherapy, immunotherapy or investigational agents =< 4 weeks
prior to the first day of study defined treatment; palliative radiation < 2 weeks;
patients who receive gamma knife radiosurgery for brain metastases are eligible if
procedure was performed > 4 weeks before treatment is started, is clinically stable
and has been on stable low dose corticosteroid treatment (e.g. dexamethasone 2
mg/day, predisolone 10mg/day for at least 14 days before start of study treatment are
eligible); ongoing hormonal therapies (luteinizing hormone-releasing hormone [LHRH]
antagonists, megestrol) are allowed

- Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor

- Patients with a known hypersensitivity to BKM120 or to its excipients

- Patients with acute or chronic liver, renal disease or pancreatitis

- Patients haves any of the following mood disorders as judged by the Investigator or a
Psychiatrist, or who meets the cut-off score of >= 12 in the Patient Health
Questionnaire (PHQ-9) or a cut-off of >= 15 in the Generalized Anxiety Disorder
(GAD-7) mood scale, respectively, or selects a positive response of '1, 2, or 3' to
questions number 9 regarding potential for suicidal thoughts in the PHQ-9
(independent of the total score of the PHQ-9)

- Medically documented history of or active major depressive episode, bipolar disorder
(I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal
attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)

- >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety

- Patients with diarrhea >= CTCAE grade 2

- Patient has active cardiac disease including any of the following:

- Left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Grated
acquisition (MUGA) scan or echocardiogram (ECHO)

- QTc > 480 msec on screening electrocardiogram (ECG) (using the QTcF formula)

- Angina pectoris that requires the use of anti-anginal medication

- Ventricular arrhythmias except for benign premature ventricular contractions

- Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with

- Conduction abnormality requiring a pacemaker

- Valvular disease with document compromise in cardiac function

- Symptomatic pericarditis

- Previous history of QTc prolongation as a result of other medication that required
discontinuation of that medication

- Congenital long QT syndrome of 1st degree relative with unexplained sudden death
under 40 years of age

- Patient has a history of cardiac dysfunction including any of the following:

- Myocardial infarction within the last 6 months, documents by persistent elevated
cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF

- History of documents congestive heart failure (New York Heart Association functional
classification III-IV)

- Documented cardiomyopathy

- Active clinically serious infections defined as >= Grade 2 according to National
Cancer Institute (NCI) CTCAE, version 4.0

- Substance abuse, medical, psychological or social conditions that may, in the opinion
of the Investigator, interfere with the patient's participation in the study or
evaluation of the study results

- Any condition that is unstable or which could jeopardize the safety of the patient
and his/her protocol compliance

- Patient has poorly controlled diabetes mellitus, steroid-induced diabetes mellitus,
or HbA1c > 7%

- Known human immunodeficiency virus (HIV) infection; because the toxicity of novel
combinations is unknown, there is concern about effects on patients with severe
chronic illnesses, such as immunosuppression found in patients with HIV; this is
particularly true in phase I studies where therapeutic benefit is uncertain; thus
patients with known HIV are traditionally excluded from phase I studies

- Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.,
active or uncontrolled infection) that could cause unacceptable safety risks or
compromise compliance with the protocol

- Significant symptomatic deterioration of lung function; if clinically indicated,
pulmonary function tests including measures of predicted lung volumes, diffusion
capacity of carbon monoxide (DLco), oxygen (O2) saturation at rest on room air should
be considered to exclude pneumonitis or pulmonary infiltrates

- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of BKM 120 (e.g., ulcerative diseases, uncontrolled nausea,
vomiting, diarrhea, malabsorption syndrome, or small bowel resection); patients with
unresolved diarrhea will be excluded as previously indicated

- Patients who have been treated with any hematopoietic colony-stimulating growth
factors (e.g., filgrastim [G-CSF], sargramostim [GM-CSF]) =< 2 weeks prior to
starting study drug; erythropoietin or darbepoetin therapy, if initiated at least 2
weeks prior to enrollment, may be continued

- Patients who have taken herbal medications and certain fruits within 7 days prior to
starting study drug; herbal medications include, but are not limited to St. John's
wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA),
yohimbe, saw palmetto, and ginseng; fruits include the CYP3A inhibitors Seville
oranges, grapefruit, pummelos, or exotic citrus fruits.

- Patients who have received wide field radiotherapy =< 4 weeks or limited field
radiation for palliation =< 2 weeks prior to starting study drug or who have not
recovered from side effects of such therapy

- Women who are pregnant or breast feeding or adults of reproductive potential not
employing an effective method of birth control; double barrier contraceptives must be
used through the trial by both sexes; oral, implantable, or injectable contraceptives
may be affected by cytochrome P450 interactions, and are therefore not considered
effective for this study; women of child-bearing potential, defined as sexually
mature women who have not undergone a hysterectomy or who have not been naturally
postmenopausal for at least 12 consecutive months (i.e., who has had menses any time
in the preceding 12 consecutive months), must have a negative serum pregnancy test =<
48 hours prior to initiating treatment

- Women are considered post-menopausal and not of child bearing potential if they have
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical
profile (e.g. age appropriate, history of vasomotor symptoms) or six months of
spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40
mlU/mL [for US only: and estradiol < 20 pg/mL] or have had surgical bilateral
oophorectomy (with or without hysterectomy) at least six weeks ago; in the case of
oophorectomy alone, only when the reproductive status of the woman has been confirmed
by follow up hormone level assessment is she considered not of child bearing

- Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, must use highly effective contraception during treatment for 4
weeks (5 T1/2) after stopping treatment; the highly effective contraception is
defined as either:

- 1) True abstinence: When this is in line with the preferred and usual lifestyle of
the subject; periodic abstinence (e.g., calendar, ovulation, symptothermal,
post-ovulation methods) and withdrawal are not acceptable methods of contraception

- 2) Sterilization: have had surgical bilateral oophorectomy (with or without
hysterectomy) or tubal ligation at least six weeks ago; in case of oophorectomy
alone, only when the reproductive status of the woman has been confirmed by follow

- 3) Male partner sterilization (with the appropriate post-vasectomy documentation of
the absence of sperm in the ejaculate); for female subjects on the study, the
vasectomized male partner should be the sole partner for that patient

- 4) Use of a combination of any two of the following (a+b):

- a) Placement of an intrauterine device (IUD) or intrauterine system (IUS)

- b) Barrier methods of contraception: condom or occlusive cap (diaphragm or
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository

- Oral contraception, injected or implanted hormonal methods are not allowed as BKM120
potentially decreases the effectiveness of hormonal contraceptives

- Women of child-bearing potential must have a negative serum pregnancy test =< 48
hours prior to initiating treatment

- Fertile males, defined as all males physiologically capable of conceiving offspring
must use condom during treatment, for 4 weeks (5 T1/2) after stopping treatment and
for additional 12 weeks (16 weeks in total after study drug discontinuation) and
should not father a child in this period

- Female partner of male study subject should use highly effective contraception during
dosing of any study agent and for 16 weeks after final dose of study therapy

- Inability to swallow oral medications

- Significant gastrointestinal disorder, in the opinion of the Investigator, could
interfere with the absorption of BKMI20 (e.g. significant, uncontrolled inflammatory
bowel disease, history of abdominal fistula or GI perforation within 6 months,
extensive small bowel resection and requirement for tube feeding or parenteral

- Patients who are currently receiving treatment with medication with a known risk to
prolong the QT interval or inducing Torsades de Pointes and the treatment cannot
either be discontinued or switched to a different medication prior to starting study
drug; please refer to table 8-2 for a list of prohibited QT prolonging drugs with
risk of Torsades de Pointes

- Patients receiving chronic treatment with steroids or another immunosuppressive
agent; Note: topical applications (e.g. rash), inhaled sprays (e.g. obstructive
airways diseases), eye drops or local injections (e.g. intr-articular) are allowed;
patients with previously treated brain metastases, who are on stable low dose
corticosteroids treatment (e.g. dexamethasone 2 mg/day, prednisolone 10 mg/day) for
at least 14 days before start of study treatment are eligible

- Patients who are currently treated with drugs known to be moderate and strong
inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued
or switched to a different medication prior to starting study drug (please note that
co-treatment with weak inhibitors of CYP3A is allowed)

- Patients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6
weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must
recover to a grade 1 before starting the trial

- Patients who have received any continuous or intermittent small molecule therapeutics
(excluding monoclonal antibodies) =< 5 effective half lives prior to starting study
drug or who have not recovered from side effects of such therapy

- No concurrent intake of valproic acid, rifampin, phenobarbital, phenytoin, or

- Patients who are currently taking therapeutic doses of warfarin sodium or any other
coumadin derivative anticoagulant

- Patient is unable or unwilling to abide by the study protocol or cooperate fully with
the investigator

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum tolerated dose (MTD) or recommended phase 2 dose of PI3K inhibitor BKM120

Outcome Description:

Adverse events (AE) will be coded and evaluated for severity using National Cancer Institute (NCI) CTCAE, version 4.0 and will be summarized by system organ class and preferred term.

Outcome Time Frame:

21 days

Safety Issue:


Principal Investigator

Alex Adjei

Investigator Role:

Principal Investigator

Investigator Affiliation:

Roswell Park Cancer Institute


United States: Food and Drug Administration

Study ID:

I 186510



Start Date:

May 2012

Completion Date:

Related Keywords:

  • Unspecified Adult Solid Tumor, Protocol Specific
  • Neoplasms



Roswell Park Cancer InstituteBuffalo, New York  14263